Loading organizations...
§ Private Profile · Palo Alto, CA, USA
Biotech company developing an AI-enabled metabolomics platform for microbial metabolite drug discovery in inflammatory diseases.
Interface Biosciences, headquartered in Palo Alto, California, is pioneering an AI-enabled, metabolomics-based drug discovery platform. This advanced platform is designed to identify low-toxicity, immune-modulating microbial metabolites derived from the microbiome, specifically targeting treatments for debilitating inflammatory diseases like inflammatory bowel disease, rheumatoid arthritis, and eczema. By synergistically leveraging principles of biological evolution, natural products research, and cutting-edge machine learning, Interface Biosciences is dedicated to developing next-generation immunotherapies. The company, founded in 2020 by CEO Hannah Wastyk (a Stanford PhD in bioengineering) and Will Van Treuren (a Stanford PhD in microbiology/immunology), recently secured significant financial backing. They raised $3 million in total funding, including an oversubscribed seed round in December 2023, notably led by investor LongeVC, represented by Sergey Jakimov.
Interface Biosciences has raised $3.0M across 1 funding round.
Interface Biosciences has raised $3.0M in total across 1 funding round.
Interface Biosciences has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 6, 2023 | $3M Seed | Gaingels, Sergey Jakimov, Seedfolio | Boom Capital, Pacific 8 Ventures, Pear VC, ULU Ventures | Announced |
Interface Biosciences has raised $3.0M in total across 1 funding round.
Interface Biosciences's investors include Gaingels, Sergey Jakimov, SeedFolio, Boom Capital, Pacific 8 Ventures, Pear VC, Ulu Ventures.